ReviewPloS one2017

Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.

Caroline S Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.